BPC-157 TB-500 dosage in the research literature

BPC-157 TB-500 dosage in the research literature

BPC-157 TB-500 dosage has no validated value for the blend. Commercial research labeling commonly pairs the two at fixed combined masses per vial — for example ~10 mg + ~10 mg, or a 20 mg combined vial — but no peer-reviewed combination dose-finding study exists, so that pairing reflects packaging convention, not evidence.

The constituent figures are animal-model figures, expressed per body weight. For the BPC-157 component, rodent studies commonly used ~10 microg/kg and ~10 ng/kg ^[1], with gastric-ulcer cytoprotection studied at 400-800 ng/kg in rats. For the TB-500 / Thymosin Beta-4 component, the range is wide: 2-18 mg/kg intraperitoneally in a rat embolic-stroke dose-response study, in which the optimal modeled dose was about 3.75 mg/kg and 18 mg/kg gave no benefit — a direct demonstration that higher is not better. None of these converts to a human regimen, and none describes the combination.

How much BPC-157 and TB-500 should be used per week?

There is no validated weekly dose for the blend. Animal doses are expressed per body weight — BPC-157 at roughly 10 microg/kg ^[1], Thymosin Beta-4 across a wide mg/kg range — which does not convert to a human weekly amount. Community weekly figures circulating online have no controlled-trial basis.

Half-life, cycling, and injection frequency

What is the half-life of BPC-157 and TB-500?

BPC-157's elimination half-life was reported as under 30 minutes (<30 min) in an animal PK study. No validated human half-life exists for either constituent at research-use doses, and none for the blend; human data on full-length Thymosin Beta-4 show dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide.

How do you cycle BPC-157 and TB-500?

There is no validated cycling protocol. Fixed-ratio vials (such as 10 mg + 10 mg) and "loading" schedules circulating online have no basis in controlled human trials. A rat stroke study found Thymosin Beta-4 dosing non-monotonic — 18 mg/kg gave no benefit — which undercuts the "loading" rationale that more is better.

How often should you inject BPC-157 and TB-500?

There is no validated dosing schedule for the blend. Community "loading then maintenance" protocols have no controlled-trial basis and should not be presented as validated dosing. The honest statement is that injection frequency for the combination is undefined in the peer-reviewed literature.

Routes studied, and the wolverine injection question

The wolverine injection question: which routes the research used

Research-community routes for the blend are predominantly subcutaneous and intramuscular, but those are not from controlled human efficacy trials. In the underlying rodent efficacy studies for both peptides, the predominant route was intraperitoneal ^[1][6][7]. Intravenous administration appears in human Phase 1 work on full-length Thymosin Beta-4 and a BPC-157 IV safety pilot, and local, intra-lesional, and topical routes appear in individual-compound wound and tendon models. No combination study defined a route for the blend.

BPC 157 TB 500 oral versus injectable routes in the literature

BPC-157 is studied as a "stable gastric" peptide, which is why BPC 157 TB 500 oral products are marketed — but blend oral products lack validated pharmacokinetics, so the marketed oral route is not evidence-backed for the combination. The injectable routes above are the ones used in the underlying studies; none was a combination study.

Reconstitution and handling

Can you mix BPC-157 with TB-500 in the same syringe?

Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated, and a common community practice is to reconstitute them separately or in a shared vial. The peer-reviewed literature does not validate co-mixing or any resulting blend; product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed, which is the more important caveat than the mechanics of the syringe.

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated. For a labeled 10 mg constituent, the reconstitution mechanics are routine peptide handling — but product identity and the actual ratio in unregulated "Wolverine" material are not guaranteed, and the TB-500-vs-full-length-Thymosin-Beta-4 identity caveat compounds the uncertainty ^[4][9].

These are handling notes from the research literature, not instructions for use. For why the regulatory framework restricts how either constituent can be compounded, see Wolverine legal status and 503A compounding access.